No Prescription |
 |
 | ||
|
Dynacirc SR Generic Isradipine |
|
| ||
No Prescription » Prescription Drugs 6 » Dynacirc SR Generic Isradipine Isradipine is in a group of drugs called calcium channel blockers. It works by relaxing the muscles of your heart and blood vessels.Isradipine is used to treat high blood pressure (hypertension). It is sometimes given with other blood pressure medications. Buy Dynacirc SR Generic Isradipine and other Prescription Drugs 6 products online at Medstore. Buy Online at Medstore - Click Here!
About Dynacirc SR Generic Isradipine: Product Type: Prescription Drugs 6 Dynacirc SR (Generic Isradipine) Dynacirc SR (Generic Isradipine) Generic Isradipine 5mg 30 Capsules 90(3 x 30) Capsules 180(6 x 30) Capsules Generic Isradipine Dynacirc SR
View more Prescription Drugs 6 No Prescription: NEW YORK, Oct. 5, 2011 /PRNewswire via COMTEX/ -- Reportlinker.com announces that a new market research report is available in its catalogue: European Pharmaceutical Market: Strategic Assessments of Leading Suppliers http://www.reportlinker.com/p0651431/European-Pharmaceutical-Market-Strategic-Assessments-of-Leading-Suppliers.html #utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication This report provides industry executives with strategically significant competitor information and analysis of the leading players in the European pharmaceutical market. The report provides a worldwide strategic overview of the pharmaceutical market, including: Sales forecast for major product segments: ethical, OTC, generics. Sales forecast for major drug categories: cardiovascular, gastrointestinal, antibiotic, CNS, respiratory, musculoskeletal, hormonal/genitourinary, dermatological, oncological, ophthalmic, and others. In addition, the report reviews major regulatory, technological, economic, demographic, and social trends with potentially significant impact on the market during the next five years, including discussion of such key issues as pricing, industry consolidation, market globalization, growing R&D cost, generics, as well as advances in genomics, proteomics, drug screening, tissue engineering, bioinformatics, and other technologies. The companies analyzed in this report include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis and Wyeth.
| ||
